Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company has once again seen record numbers as the company unveils its 2nd quarter financials. The numbers include the 6th consecutive quarter of revenue growth at 13.6 million dollars in Q2-23, up 184% over Q2-22.
Saviuk telling Proactive the number company also saw 6th consecutive quarter of adjusted EBITDA loss reduction at $1.7 million, which is a 53% improvement. The drugs asthma Enerzair and Atectura continues to perform with total prescriptions for the 12 months ending April 30, 2023 exceeded 45,000, up 654% over April 30, 2022. Looking ahead, the company projects revenues to exceed $60 million for the year, expecting continued growth in the third quarter.